Skip to content
Screener

Exelixis EXEL Total Liabilities & Equity

Total Liabilities & Equity at other companies

Eli Lilly logo
Eli LillyLLY
$142.28B+41.0%
Pfizer logo
PfizerPFE
$207.62B-0.2%
Kura Oncology logo
Kura OncologyKURA
$652.55M-12.3%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$435.79M+58.9%
Immunome logo
ImmunomeIMNM
$619.79M+80.9%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$924M-14.0%

Other financials

Income statement

See full
Revenue$628.7M+10.6%
Gross profit$608.0M+10.8%
Operating income$248.4M+16.3%
Net income$212.1M+14.7%
EPS (diluted)$0.82+26.2%

Balance sheet

See full
Cash & equivalents$281.4M+71.2%
Total debt$165.9M-7.7%
Total equity$1.8B-9.3%
Total assets$2.5B-6.9%

Cash flow

See full
Operating cash flow$307.7M+528%
CapEx$6.8M+140%
Free cash flow$300.9M+552%

Valuation

See full
Market cap$12.93B+27.4%
Enterprise value$12.82B+26.1%
P/E15×-1.8×
P/S5.3×+0.8×

Profitability

See full
Gross margin96.5%-0.1pp
Operating margin39.9%+8.5pp
Net margin35.3%+8.3pp
FCF margin48.1%+14.3pp

Returns & leverage

See full
Return on equity44.4%+15.4pp
Debt / equity0.1×0.0×
Current ratio3.5×-0.1×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Exelixis’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q3 2026
Accession
0000939767-26-000098
Line itemJune 30, 2026December 31, 2025
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 248,885 and 262,483 at June 30, 2026, and December 31, 2025, respectively249262
Additional paid-in-capital2,108,0592,234,411
Accumulated other comprehensive income (loss)(2,013)3,476
Accumulated deficit(262,533)(76,830)
Total stockholders’ equity1,843,7622,161,319
Total liabilities and stockholders’ equity$2,494,234$2,844,423

Item 1. Financial Statements.

FAQ

What is Exelixis's total liabilities & equity?
Exelixis (EXEL) reported total liabilities & equity of $2.49B in Q2 2026.
How has Exelixis's total liabilities & equity changed year-over-year?
Exelixis's total liabilities & equity decreased by 6.9% year-over-year, from $2.68B to $2.49B.
What is the long-term trend for Exelixis's total liabilities & equity?
Over 5 years (2020 to 2025), Exelixis's total liabilities & equity has grown at a 5.9% compound annual growth rate (CAGR), from $2.14B to $2.84B.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Exelixis's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude